期刊： CLINICAL PHARMACOKINETICS, 2023; 62 (8)
Darolutamide is a next-generation androgen receptor signaling inhibitor (ARSI) currently approved for the treatment of nonmetastatic castration-resist......
期刊： CLINICAL PHARMACOKINETICS, 2023; 62 (12)
Finerenone, a selective and nonsteroidal antagonist of the mineralocorticoid receptor, has received regulatory approval with the indication of cardior......
期刊： CLINICAL PHARMACOKINETICS, 2023; 62 (7)
Background and objectiveUp to 90% of patients with castration-resistant prostate cancer (CRPC) will develop symptomatic bone metastases requiring pain......
期刊： CLINICAL PHARMACOKINETICS, 2023; 62 (10)
Background and ObjectiveIn treating opioid use disorder (OUD), subcutaneous (SC) extended-release buprenorphine (BPN) depots, e.g., CAM2038, have been......
期刊： CLINICAL PHARMACOKINETICS, 2023; 62 (10)
Imeglimin (PXL008, EMD-387008, Twymeeg & REG;) is a first-in-class novel oral hypoglycemic agent, launched in Japan, for the treatment of type 2 d......
期刊： CLINICAL PHARMACOKINETICS, 2023; 62 (5)
BackgroundCarfilzomib is an irreversible second-generation proteasome inhibitor that has a short elimination half-life but much longer pharmacodynamic......
期刊： CLINICAL PHARMACOKINETICS, 2023; ()
Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor designed to overcome mechanisms of resistance associated with crizotinib, is ......
期刊： CLINICAL PHARMACOKINETICS, 2023; 62 (1)
Background and Objective Infants and neonates present a clinical challenge for dosing drugs with high interindividual variability due to these patient......
期刊： CLINICAL PHARMACOKINETICS, 2023; 62 (7)
The US Food and Drug Administration's Animal Rule provides a pathway for approval of drugs and biologics aimed to treat serious or life-threatening co......
期刊： CLINICAL PHARMACOKINETICS, 2023; 62 (1)
BackgroundPost-placement menstrual bleeding pattern changes with intrauterine contraceptives (IUCs), including levonorgestrel-releasing intrauterine s......
期刊： CLINICAL PHARMACOKINETICS, 2023; 62 (8)
Background Janagliflozin is a novel sodium-glucose cotransport-2 inhibitor. Despite its remarkable effect in glycemic control, no systematic research ......
期刊： CLINICAL PHARMACOKINETICS, 2023; 62 (2)
Background Levosimendan (LVSMD) is a calcium-sensitizer inotropic and vasodilator agent whose use might have a beneficial effect on the weaning of ven......
期刊： CLINICAL PHARMACOKINETICS, 2023; 62 (9)
Background and Objective Voriconazole is an important broad-spectrum anti-fungal drug with nonlinear pharmacokinetics. The aim of this single centre f......
期刊： CLINICAL PHARMACOKINETICS, 2023; 62 (12)
Introduction Immune checkpoint inhibitors improved survival of advanced stage non-small cell lung cancer patients, but the overall response rate remai......
